Characterization of cytochrome P450 enzymes and P-glycoprotein involved in the metabolism and transport of a new anti-angiogenic agent KR-31831

Drug Development Research

Volumn 66, Issue 1, 2005, Pages 40-49

  Kim, Hui Hyun ^a   Ji, Hye Young ^a   Lee, Hye Won ^a   Kim, Soon Ai ^a   Lee, Seonkyoung ^b   Yi, Kyu Yang ^b   Lee, Hye Suk ^a,b  

^a Wonkwang University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

CYP3A4; Drug drug interaction; In vitro metabolism; KR 31831; P glycoprotein

Indexed keywords

6 AMINO 4 [N (4 CHLOROPHENYL) N (1H IMIDAZOL 2 YLMETHYL)AMINO] 3 HYDROXY 2 DIMETHYLOXYMETHYL 3,4 DIHYDRO 2 METHYL 2H 1 BENZOPYRAN; 6 AMINO 4 [N (4 CHLOROPHENYL) N (1H IMIDAZOL 2 YLMETHYL)AMINO] 3 HYDROXY 2 HYDROXYMETHYL 3,4 DIHYDRO 2 METHYL 2H 1 BENZOPYRAN; AMINE; ANGIOGENESIS INHIBITOR; BENZENE DERIVATIVE; BENZOPYRAN DERIVATIVE; CHLORINE DERIVATIVE; COMPLEMENTARY DNA; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIETHYLTHIOCARBAMATE; DRUG METABOLITE; FLAVONE DERIVATIVE; GENISTEIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; IMIDAZOLE DERIVATIVE; INDOMETACIN; KETOCONAZOLE; KR 31831; N (4 CHLOROPHENYL) N (1H IMIDAZOL 2 YLMETHYL)AMINE; PACLITAXEL; QUERCETIN; QUINIDINE; SULFAPHENAZOLE; TARIQUIDAR; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSPORT; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STANDARD; TANDEM MASS SPECTROMETRY;

EID: 32544439240     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.20037     Document Type: Article

References (33)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Bourne M, Meunier V, Berger Y, Fahre G. 1996. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
3. Crespi CL, Chang TK, Waxman DJ. 1998. High-performance liquid Chromatographic analysis of CYP2C8-catalyzed paclitaxel 6α-hydroxylation. Methods Mol Biol 107:123-127.
4. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. 2001. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29.
5. Eagling VA, Tjia JF, Back DJ. 1998. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
6. Ferreira CG, Huisman C, Giaccone G. 2002. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 41:57-77.
7. Gtbson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. 2002. Receptor-dependent transcriptional activation of CYP3A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165-206.
8. Gres MC, Julian B, Bourne M, Meunier V, Roques, C, Berger M, Boulenc X, Berger Y, Fahre G. 1998. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 15:726-733.
9. Guengerich FP. 1999. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 39:1-117.
10. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorli I, Gerloff T, Roots I, Eichelbaume M, Brinkmann U. 2000. Functional polymorphism of the human multidrug-resistant gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 97:4373-4378.
11. Kim N, Lee S, Yi KY, Yoo S, Kim G, Lee CO, Park SH. 2003. Identification of a novel antiangiogenic agent: 4-(N-imidazol-2-ylmethyl)aminobenzopyran analogues. Bioorg Med Chem Lett 13:1661-1663.
12. Kim SJ, Lee SS, Ji HY, Lee HI, Lee S, Yi KY, Yoo SE, Hwang J, Lee HS. 2004. Determination of a novel antiangiogenic agent KR-31831 in rat plasma by liquid chromatography-tandem mass spectrometry. Anal Lett 37:295-304.
13. Kim SJ, Lee HL Ji HY, Moon Y, Paek IB, Lee S, Yi KY, Yoo SD, Lee HS. 2005a. Pharmacokinetics of a novel antiangiogenic agent KR-31831 in rats. Biopharm Drug Dispos 26:21-26.
14. Kim HH, Paek IB, Ji HY, Lee S, Yi KY, Lee HS. 2005b. Metabolism of a novel antiangiogenic agent KR-31831 in rats using liquid chromatography- electrospray mass spectrometry. J Sep Sci 28:1818-1822.
15. Kronbach T. 1991. Bufuralol, dextrmethorphan and debrisoquine as prototype substrates for human P450IID6. Methods Enzymol 206:509-517.
16. Leemann T, Transon C, Dayer P. 1993. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34.
17. Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty B, Lee CA. 1998. Characterization of the selectivity and mechanism of human Cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Disp 26:609-616.
18. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. 1999. The molecular interaction of the affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128:403-411.
19. Perloff MD, Von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ. 2000. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618-628.
20. Plant NJ, Gibson GG. 2003. Evaluation of the toxicological relevance of CYP3A4 induction. Curr Opin Drug Dis Dev 6:50-56.
21. Semenza GL. 2003. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54:17-28.
22. Sepp-Lorenzio L, Thomas K. 2002. Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development. Exp Opin Invest Drugs 11:1447-1465.
23. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
24. Silverman JA. 2000. P-Glycoprotein. In: Levi RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins. p 135-144.
25. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miner JO. 1993. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
26. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz, JS, Shader RI. 1998. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J Clin Pharmacol 38:106-111.
27. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrme P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
28. Wacher VJ, Salphati L, Benet LZ. 1996. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Del Rev 20:99-112.
29. Walle UK, Walle T. 1998. Taxol Transport by human intestinal epithelial Caco-2 cells. Drug Metab Disp 26:343-346.
30. Wang JS, Wen X, Backman JT, Taavitsainen P, Neubonnen PJ, Kivisto KT. 1999. Midazolam α-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol 85:157-161.
31. Wrighton SA, Thummel KE. 2000. CYP3A. In: Levi RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins. p 115-133.
32. Wrighton SA, Stevens JC, Becker GW, Vandenbranden M. 1993. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240-245.
33. Yamano S, Tatsuno J, Gonzalez FJ. 1990. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29:1322-1329.